Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
| Autor: | Rodriguez-Freixinos, V., Fariñas-Madrid, L., Gil-Martin, M., Barretina-Ginesta, P., Romeo, M., Villacampa, G., Pardo, B., Ahmed, H., Recalde, S., Piulats, J.M., Gómez-Plaza, M.C., Gil-Moreno, A., Sala, E., Martínez-Román, S., Ponce, J., Meléndez, C., Carballas, E., Dienstmann, R., Oaknin, A. |
|---|---|
| Zdroj: | In Gynecologic Oncology February 2019 152(2):270-277 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect